Covid-19
[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.
24 Aug, 2021 | 10:06h | UTCRelated:
Commentary on Twitter
@TogetherTrial Manuscript Pre-print regarding #Fluvoxamine for early #COVID19 is online athttps://t.co/teHqMlowld
demonstrating ~30% relative reduction in ER visits / hospitalizations with fluvoxamine 100mg 2x/day in a 10-site, double-blind randomized trial. #IDtwitter pic.twitter.com/727by0lqft— David Boulware, MD MPH (@boulware_dr) August 23, 2021
How will Delta evolve? Here’s what the theory tells us.
24 Aug, 2021 | 09:58h | UTCHow will Delta evolve? Here’s what the theory tells us – The Conversation
Opinion | The FDA really did have to take this long – “If vaccine approval feels maddeningly scrupulous, that’s because the alternative is worse”.
24 Aug, 2021 | 10:01h | UTCThe FDA Really Did Have to Take This Long – The Atlantic
Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience – “Despite negligible fatality, complications including hospitalization, hypoxemia, and pneumonia were more frequent in children and adolescents with COVID-19 than with influenza”.
24 Aug, 2021 | 09:51h | UTCRelated:
Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.
AAP Guidance: Post-COVID-19 conditions in children and adolescents.
Cohort study: Risk factors for long covid in previously hospitalized children.
Deaths from COVID ‘incredibly rare’ among children.
Perspective | How should schools and daycare treat colds in the covid age? It’s complicated. – “Will every sniffle and cough be treated as potential Covid until proven otherwise?”.
24 Aug, 2021 | 09:53h | UTCHow Should Schools And Daycare Treat Colds In The Covid Age? It’s Complicated. – Romper
How I Do It: Considering lung transplantation for patients with COVID-19.
24 Aug, 2021 | 09:55h | UTCHow I Do It: Considering lung transplantation for patients with COVID-19 – CHEST
Related:
Report: Lung transplantation for 3 patients with severe COVID-19
COVID vaccines protect against Delta, but their effectiveness wanes.
24 Aug, 2021 | 09:57h | UTCCOVID vaccines protect against Delta, but their effectiveness wanes – Nature
Original study: [Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.
Cluster RCT: Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections.
23 Aug, 2021 | 00:01h | UTC
Commentary on Twitter
Even though we are tired, we should continue trying to educate the public through social media – “Social media messages recorded by health professionals before the winter holidays in the US led to a significant reduction in holiday travel and subsequent COVID-19 infections” https://t.co/kyeKTe4sJn
— gilberto lopes (@GlopesMd) August 22, 2021
Among patients receiving mRNA vaccines, clinically significant symptoms were more frequent following dose 2, following dose 1 in patients with previous SARS-CoV-2 infection, and in those who received the Moderna vaccine.
22 Aug, 2021 | 23:54h | UTC
Commentary on Twitter
New @JAMA_current paper says @moderna_Tx caused 2.3x the number of "significant" symptoms compared to @pfizer in a sample of 950 people.
Moderna also produced more antibodies. Raising the question of what a third dose, which produces still MORE, will do.https://t.co/drvhhsnpHo
— Alex Berenson (@AlexBerenson) August 16, 2021
[Preprint] Study shows symptomatic breakthrough infections are probably less transmissible than SARS-CoV-2 infections in unvaccinated individuals.
22 Aug, 2021 | 23:59h | UTC
Commentary on Twitter (thread – click for more)
Did you hear vaccinated people with Delta “have just as much virus in their nose so are just as infectious as unvaccinated”?
Turns out vaccinated people have significantly less culturable virus present at the same Ct count
They are LESS INFECTIOUS 💥 https://t.co/OX0Ul0ntWc pic.twitter.com/3vDQSJ6j84
— Alasdair Munro (@apsmunro) August 22, 2021
RCT: Awake prone positioning reduces the need for intubation in patients with COVID-19.
23 Aug, 2021 | 00:03h | UTCInvited commentary: Awake prone positioning in COVID-19: is tummy time ready for prime time?
Related:
Commentary on Twitter
Awake prone positioning of pts w/ hypoxaemic respiratory failure due to #COVID19 reduces incidence of treatment failure & need for intubation w/o any signal of harm
Meta-trial from the Awake Prone Positioning Meta-Trial Group https://t.co/GuDdjPnVps pic.twitter.com/ZS08uQN1gE
— The Lancet Respiratory Medicine (@LancetRespirMed) August 21, 2021
Evidence mounts that people with breakthrough infections can spread Delta easily.
22 Aug, 2021 | 23:57h | UTCOriginal study: Shedding of Infectious SARS-CoV-2 Despite Vaccination when the Delta Variant is Prevalent – Wisconsin, July 2021 – medRxiv
Commentary on Twitter
The evidence that supports Delta breakthrough infections ability to spread (and why fully vaccinated people need to 😷 up)https://t.co/27NOf6mYCM @NatGeo by @Ecquis w/ studies and input by @GuptaR_lab and @KasenRiemersma
— Eric Topol (@EricTopol) August 20, 2021
Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.
22 Aug, 2021 | 23:51h | UTCInvited Commentary: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
Related:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)
Commentary on Twitter
NEW Research—Heterologous ChAdOx1 nCov-19–BNT162b2 immunisation w/ 10–12-week interval is well tolerated & improves immunogenicity vs homologous ChAdOx1 nCov-19 vax w/ 10–12-week interval & BNT162b2 vax w/ 3-week interval
Study from Prof Sander & co https://t.co/VAB54NokSi pic.twitter.com/wfeBsvoKhO
— The Lancet Respiratory Medicine (@LancetRespirMed) August 13, 2021
Study Commentaries: Non-invasive ventilation for COVID 19 patients. The Recovery RS trial.
22 Aug, 2021 | 23:52h | UTCCommentary 1: JC: Non-invasive ventilation for COVID 19 patients. The Recovery RS trial – St Emlyn’s
CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil – Effectiveness against symptomatic disease was 46.8%, 55.5% against hospitalization, and 61.2% against deaths.
22 Aug, 2021 | 23:48h | UTCEditorial: Real world effectiveness of covid-19 vaccines
Related: CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness. (several texts on the subject)
[Preprint] SARS-CoV-2 aerosol transmission in schools: theoretical effectiveness of different interventions – “Combined interventions (i.e., natural ventilation, masks, and HEPA filtration) were the most effective (≥ 30-fold decrease)”.
22 Aug, 2021 | 23:50h | UTCSARS-CoV-2 aerosol transmission in schools: the effectiveness of different interventions – medRxiv
Related: The right way to protect our children and return to in-person learning – CNN
Commentaries on Twitter
Interesting modelling study for schools: (theoretically) most effective is open windows, then masks, then HEPA filter. Would be good to do real world tests though. https://t.co/MDFNqNNUI3 pic.twitter.com/xGSodClipO
— Paul Glasziou (@PaulGlasziou) August 21, 2021
This is not real evidence supporting real policy choices as they are really carried out in the real world.
Instead, this is theoretical bioplausibility spun into a full paper.
I hope folks can still tell the two aparthttps://t.co/znwtiaKZ2g
— Vinay Prasad MD MPH (@VPrasadMDMPH) August 20, 2021
Observational data from Canada: Effectiveness of mRNA covid-19 vaccines was 91% against symptomatic disease and 98% against hospitalization and deaths.
22 Aug, 2021 | 23:47h | UTCEditorial: Real world effectiveness of covid-19 vaccines
[Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.
20 Aug, 2021 | 10:03h | UTCCommentaries:
Pfizer vaccine effectiveness declines faster than AstraZeneca – study – Evening Standard
Commentary on Twitter
New large UK study confirms attrition of @Pfizer vaccine effectiveness vs Delta infections over time https://t.co/K6YRyAQq4o "By roughly 4 1/2 months after the 2nd dose, Pfizer’s shot will probably be about on par with Astra’s at preventing infections with a high viral burden" pic.twitter.com/x1Nl2BkWfn
— Eric Topol (@EricTopol) August 19, 2021
Covid-19: How many variants are there, and what do we know about them?
20 Aug, 2021 | 10:00h | UTCCovid-19: How many variants are there, and what do we know about them? – The BMJ
Commentary on Twitter
Eight notable variants of SARS-CoV-2 have been found since September 2020. @emahase_ reviews the line-up so far https://t.co/jmzfnbudoL
Watch this video showing how the variants have spread around the globe: pic.twitter.com/KwBl6B48Dy
— The BMJ (@bmj_latest) August 19, 2021
New SARS-CoV-2 variants have changed the pandemic. What will the virus do next?
20 Aug, 2021 | 09:58h | UTCNew SARS-CoV-2 variants have changed the pandemic. What will the virus do next? – Science
Commentary on Twitter
I really, really wish Covid deniers and minimizers would read this outstanding @ScienceMagazine piece by @kakape on the delta variant and how it has completely changed this pandemic – FOR THE WORSEhttps://t.co/liIC9NpGOJ pic.twitter.com/UkCieUUCpK
— Madhu Pai, MD, PhD (@paimadhu) August 19, 2021
The Origins of SARS-CoV-2: A Critical Review.
20 Aug, 2021 | 09:52h | UTCThe Origins of SARS-CoV-2: A Critical Review – Cell
Related:
Fauci says natural origins theory of coronavirus is still the most likely.
A grim warning from Israel: Vaccination blunts, but does not defeat Delta.
20 Aug, 2021 | 09:56h | UTCA grim warning from Israel: Vaccination blunts, but does not defeat Delta – Science
Delta’s rise is fuelled by rampant spread from people who feel fine.
20 Aug, 2021 | 09:54h | UTCDelta’s rise is fuelled by rampant spread from people who feel fine – Nature
Original study: Transmission dynamics and epidemiological characteristics of Delta variant infections in China – medRxiv
Post-Covid-19 Tachycardia Syndrome: A distinct phenotype of Post-acute Covid-19 Syndrome.
20 Aug, 2021 | 09:51h | UTC
Commentary on Twitter
Post-COVID19 tachycardia syndrome(s): nice proposal for phenotypeshttps://t.co/XI75HCGYUH pic.twitter.com/yg303QXd1E
— Otavio Ranzani (@otavio_ranzani) August 18, 2021
Long COVID-19: A Primer for Cardiovascular Health Professionals, on Behalf of the CCS Rapid Response Team.
20 Aug, 2021 | 09:49h | UTC